NSE: CONCORDBIO · 9 November 2026
- Concord Biotech has fallen 11.28% over 2 trading sessions; today's move is -2.52%.
- Concord Biotech announced the allotment of 10,46,16,204 fully paid-up bonus equity shares of ₹1 each in the proportion of 1:1 to eligible shareholders whose names appeared on the register of members as of the record date of November 4, 2026. Consequent to this allotment, the company's paid-up equity share capital increased to ₹20,92,32,408 divided into 20,92,32,408 equity shares. This corporate action reflects management's confidence in the company's sustained profitability and operational stability.
- Trading volume was 1.39 times the 20-day average daily volume.
Concord Biotech share price: 11.28% decline over 2 trading sessions
Concord Biotech Ltd. shares declined 2.52% on Monday, closing at ₹596.80 compared to the previous close of ₹612.20. The stock opened at ₹620.90, touched an intraday high of ₹625.20 and a low of ₹592.50.
While the broader Nifty index closed relatively flat with a minor gain of 0.06%, the sector benchmark Nifty Pharma recorded a strong positive movement, rising 3.42%. Concord Biotech's downward movement ran counter to the broader sector's upward trend, reflecting stock-specific selling pressure despite positive sectoral tailwinds.
The price movement coincides with ongoing developments following the company's recent corporate actions, including the allotment of bonus equity shares in the ratio of 1:1 following the November 4, 2026 record date, and solid Q2 FY27 financial results reporting a 25% year-on-year revenue increase to ₹309.1 crores. However, there is no direct evidence linking these recent corporate milestones or prior financial disclosures as an immediate day-trigger for today's specific decline.
4.14 lakh shares traded by 9 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 2.99 lakh shares (1.39 times). The five-day average daily volume was 4.96 lakh shares. Separately, the NSE report for 9 November 2026 showed 1.78 lakh shares delivered, representing 43.06% of that day’s traded volume. The same report recorded 36,585 trades.
Concord Biotech fell 2.52% despite a positive 3.42% move in the Nifty Pharma sector index, with volume exceeding its 20-day average at 1.39x. As no fresh same-day fundamental catalyst was announced, the move reflects stock-specific selling pressure and profit-taking after recent volatility.
Latest Company Developments
Concord Biotech announced the allotment of 10,46,16,204 fully paid-up bonus equity shares of ₹1 each in the proportion of 1:1 to eligible shareholders whose names appeared on the register of members as of the record date of November 4, 2026. Consequent to this allotment, the company's paid-up equity share capital increased to ₹20,92,32,408 divided into 20,92,32,408 equity shares. This corporate action reflects management's confidence in the company's sustained profitability and operational stability.
Expands the company's equity base and enhances liquidity for shareholders.
The company reported consolidated revenue of ₹309.1 crores for the second quarter ended September 30, 2026, marking a 25% year-on-year growth driven by broad-based performance across geographies and product categories. EBITDA stood at ₹104.4 crores with an EBITDA margin of 33.8%, while Profit After Tax (PAT) reached ₹69.6 crores, up 10.3% year-on-year. During the quarter, the firm also launched its new dermatology division, Inspira, and secured two ANDA approvals for Tofacitinib and MMF OS.
Provides a comprehensive overview of the company's operating performance, margin dynamics, and strategic product expansions.
Concord Biotech announced the successful completion of the US Food and Drug Administration (USFDA) inspection at its Unit II formulation facility located in Valthera, Ahmedabad. The inspection concluded with one minor procedural observation unrelated to Good Manufacturing Practices (GMP). Management noted that this reinforces the company's compliance standards and supports continuity of international supplies.
Maintains regulatory compliance standing and supports uninterrupted exports to regulated global markets like the United States.
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.84% on 30 September 2026. This compares with 4.40% on 30 June 2026, a change of +1.44 percentage points.
The filing reported 22 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution and market uptake of the newly launched dermatology division, Inspira
- Commercialization progress following recent ANDA approvals for Tofacitinib and MMF OS
- Operational performance and margin recovery trends in upcoming quarterly financial results
- Post-bonus share liquidity and trading volume adjustments in the cash segment
Other Dated Coverage
- Concord Biotech Share Price Today: Rises 12.61% in 2 Trading Sessions | 4 November 2026 — 4 November 2026
- Concord Biotech Share Price Today: Falls 10.56% in 2 Trading Sessions | 29 October 2026 — 29 October 2026
- Concord Biotech Share Price Falls 8.17% Intraday, Closes 7.77% Lower | 28 October 2026 — 28 October 2026
More Concord Biotech news and dated analysis →
Frequently Asked Questions
What is the latest Concord Biotech company news?
Concord Biotech announced the allotment of 10,46,16,204 fully paid-up bonus equity shares of ₹1 each in the proportion of 1:1 to eligible shareholders whose names appeared on the register of members as of the record date of November 4, 2026. Consequent to this allotment, the company's paid-up equity share capital increased to ₹20,92,32,408 divided into 20,92,32,408 equity shares. This corporate action reflects management's confidence in the company's sustained profitability and operational stability.
How strong was Concord Biotech’s trading volume?
4.14 lakh shares traded, 1.39 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.